Initiation of share buyback programme to meet obligations for share-based incentives
8 November 2023
Announcement No. 31
Initiation of share buyback programme to meet obligations for share-based incentives
The Board of Directors of NKT A/S has decided to exercise the authority to buy back shares granted by the Annual General Meeting on 25 March 2021. The authorization is valid in the period until 31 March 2026 and the Board of Directors is authorised to arrange for acquisition of the Company’s own shares up to a nominal value of 10% of the share capital. The authorization was partly utilized in connection with similar share buyback programmes in 2022 and earlier in 2023.
The purpose of the share buyback programme is to meet obligations relating to the Company’s share-based incentive programmes for employees.
The share buyback programme will run from 8 November 2023 and end no later than 10 November 2023. During this period, NKT A/S will buy its own shares up to a maximum of 50,000 shares in accordance with Regulation No. 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and Commission Delegated Regulation (EU) 2016/1052, also referred to as the Safe Harbour-rules.
- NKT A/S is required to retain a lead manager who is to make its own trading decisions independently of and without influence from the Company and execute the share buyback programme within the announced limits. NKT A/S has designated Danske Bank A/S as its lead manager for the share buyback programme.
- Under the share buyback programme, NKT A/S may repurchase up to 50,000 shares, corresponding to 0.09% of the current share capital of NKT A/S, for an amount up to maximum DKK 25m.
- No shares may be bought back at a price exceeding the higher of (i) the share price of the latest independent trade and (ii) the highest current independent bid at Nasdaq Copenhagen at the time of trading in compliance with the authority.
- The maximum number of NKT A/S shares that may be purchased on each business day may not exceed 25% of the average daily trading volume of NKT A/S shares on Nasdaq Copenhagen during the 20 trading days preceding the date of purchase.
Investor Relations: Michael Nass Nielsen, Head of Investor Relations, tel: +45 2494 1654
Press: Louise W. Naldal, Head of Group Communications, tel: +45 2982 0022
AttachmentTo view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Scatec at COP28: Accelerating renewable energy transition from Egypt to South Africa2.12.2023 14:01:22 CET | Press release
Dubai, 2 December 2023: This week, Scatec ASA, a leading renewable energy company, is actively engaging in the UN Climate Change Conference in Dubai (COP28). Our focus is to underscore renewable energy as an unequivocal solution to climate change and emphasise the critical need for increased green energy investments in emerging markets. COP28 serves as a pivotal platform for global stakeholders to reinforce commitments aimed at averting catastrophic consequences of climate change. Scatec aligns with climate experts in stressing the urgency of the situation and the imperative to continue advancing towards the objectives outlined in the Paris Agreement. There's no time to waste, and collective progress is crucial for safeguarding our planet's future. “We are at COP28 to highlight the key role renewable energy must play in our energy future, "At COP28, our focus is on underscoring the crucial role renewable energy must assume in shaping our energy future, particularly in emerging markets,
Unplugged Performance Introduces UP INVINCIBLE®: A Game-Changer for Tesla Cybertruck Enthusiasts2.12.2023 05:06:20 CET | Press release
HAWTHORNE, Calif., Dec. 01, 2023 (GLOBE NEWSWIRE) -- Unplugged Performance, the industry leader in performance upgrades for Tesla vehicles, debuts a new chapter in Tesla tuning with the arrival of their UP INVINCIBLE® product line. UP INVINCIBLE® is tailored exclusively for Tesla Cybertruck owners who want to push the limits of on-road and off-road performance. The unveiling took place at Unplugged Performance’s celebratory afterparty for Tesla's highly anticipated Cybertruck delivery event on November 30th. Hosted at the company's headquarters in Hawthorne, California, neighboring Tesla Design Studio, SpaceX, and Starlink, the event drew a capacity crowd, reflecting the immense enthusiasm for this innovative product range. UP INVINCIBLE® represents a concerted effort to harness and amplify the rugged DNA of the Cybertruck, making it even more robust and capable in a variety of challenging environments. During the event, Ben Schaffer, CEO of Unplugged Performance, presented an extensiv
Junshi Biosciences Announces New Chemical Entity Application for Toripalimab Accepted by Australia’s TGA2.12.2023 04:39:35 CET | Press release
SHANGHAI, China, Dec. 01, 2023 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences,” HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced that the Therapeutic Goods Administration of the Australian Government Department of Health and Aged Care (TGA) has accepted the New Chemical Entity (NCE) application for toripalimab in combination with cisplatin and gemcitabine, for the first-line treatment of adults with metastatic or recurrent locally advanced nasopharyngeal carcinoma (NPC), and for toripalimab, as a single agent, for the treatment of adults with recurrent, unresectable, or metastatic NPC with disease progression on or after platinum-containing chemotherapy. Additionally, the TGA has also granted an orphan drug designation to toripalimab for the treatment of NPC. This NCE application was submitted through Project Orbis, an initiative of
Terra Balcanica Announces Private Placement Financing1.12.2023 23:00:00 CET | Press release
NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, Dec. 01, 2023 (GLOBE NEWSWIRE) -- Terra Balcanica Resources Corp. (“Terra” or the “Company”) (CSE:TERA) announces the intent to complete a non-brokered, private placement (“Private Placement”) for gross proceeds of up to $150,000 through the issuance of up to 3,750,000 common shares (“Common Shares”) at a purchase price of $0.04 per share. The Common Shares will be offered by way of prospectus exemptions in Canada and the Common Shares sold in the Private Placement will be subject to a hold period of four months plus one day. The Closing Date is expected to occur on or about December 11th, 2023, subject to regulatory approvals, including the approval by the CSE and certain other customary conditions including, but not limited to, execution of subscription agreements between the Company and the subscribers. The Private Placement will be utilized for opportuniti
Oxurion Receives Transparency Notifications from Atlas Special Opportunities LLC1.12.2023 19:00:00 CET | Press release
Regulated Information Leuven, BELGIUM, Boston, MA, US – December 1, 2023 – 7.00 PM CET Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing next generation standard of care ophthalmic therapies, with clinical stage assets in vascular retinal disorders, today announced that, pursuant to Belgian Transparency legislation1 it has received transparency notifications as follows: Oxurion received a first transparency notification on November 22, 2023, from Atlas Special Opportunities, LLC indicating that as of November 13, 2023, it held 0 shares of the then outstanding 3,112,043,514 shares, and therefore crossed below the threshold (3%) by virtue of the sale of voting securities. See Annex 1. Oxurion received a second transparency notification on November 29, 2023, from Atlas Special Opportunities, LLC indicating that as of November 17, 2023, it held 241,545,893 shares of the then outstanding 3,489,458,972 shares, and therefore crossed above the threshold (5%) by virtu